1-{4-[(Pyridin-4-yl)methyl]piperazin-1-yl}ethan-1-one | 942486-74-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-{4-[(Pyridin-4-yl)methyl]piperazin-1-yl}ethan-1-one
• 英文别名: 1-[4-(pyridin-4-ylmethyl)piperazin-1-yl]ethanone
• CAS: 942486-74-0
• 化学式: C₁₂H₁₇N₃O
• mdl: MFCD13580930
• 分子量: 219.286
• InChiKey: ZIXNPRGBGUJJLT-UHFFFAOYSA-N

物化性质

• 沸点：
  382.9±37.0 °C(Predicted)
• 密度：
  1.145±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  36.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-{4-[(Pyridin-4-yl)methyl]piperazin-1-yl}ethan-1-one 在 盐酸 作用下， 生成 1-(4-吡啶甲基)哌嗪
  参考文献：
  名称：

  Discovery and biological evaluation of adamantyl amide 11β-HSD1 inhibitors

  摘要：

  A series of adamantyl amide 11 beta-HSD1 inhibitors has been discovered and chemically modified. Selected compounds are selective for 11 beta-HSD1 over 11 beta-HSD2 and possess excellent cellular potency in human and murine 11 beta-HSD1 assays. Good pharmacodynamic characteristics are observed in ex vivo assays. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.02.057
• 作为产物：
  描述：

  4-氯甲基吡啶 、 1-乙酰哌嗪 在 potassium iodide 作用下， 以 乙醇 为溶剂， 生成 1-{4-[(Pyridin-4-yl)methyl]piperazin-1-yl}ethan-1-one
  参考文献：
  名称：

  Discovery and biological evaluation of adamantyl amide 11β-HSD1 inhibitors

  摘要：

  A series of adamantyl amide 11 beta-HSD1 inhibitors has been discovered and chemically modified. Selected compounds are selective for 11 beta-HSD1 over 11 beta-HSD2 and possess excellent cellular potency in human and murine 11 beta-HSD1 assays. Good pharmacodynamic characteristics are observed in ex vivo assays. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.02.057

文献信息

• [EN] 2,5-DIALKYL-4-H/HALO/ETHER-PHENOL COMPOUNDS<br/>[FR] COMPOSÉS 2,5-DIALKYL-4-H/HALO/ÉTHER-PHÉNOL
  申请人：TANSNA THERAPEUTICS INC

  公开号：WO2016190871A1

  公开（公告）日：2016-12-01

  The present disclosure provides phenolic compounds useful in the treatment of neurological conditions such as convulsions and tremors, having the structure of Formula (I): wherein R2, R4, R5, & R6, are as defined in the detailed description; pharmaceutical compositions comprising at least one of the compounds; and methods for treating neurological conditions.

  本公开提供了对神经系统疾病如抽搐和震颤有用的酚类化合物，其结构如下式（I）：其中R2、R4、R5和R6如详细描述中所定义；包括至少一种该化合物的药物组合物；以及治疗神经系统疾病的方法。
• [EN] 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES<br/>[FR] 3-IMIDAZOLYL-INDOLES POUR LE TRAITEMENT DE MALADIES PROLIFÉRATIVES
  申请人：NOVARTIS AG

  公开号：WO2008119741A2

  公开（公告）日：2008-10-09

  [EN] The invention relates to 3-heterocyclyl indolyl compounds capable of inhibiting the interaction between p53, or variants thereof, and MDM2 and/or MDM4, or variants thereof, respectively, said compounds having the formula (I) wherein R¹, R², R³, R⁴, R^A, Y and Y are as defined in the specification. Due to their activity, the compounds are useful in the treatment of various disorders and diseases mediated by the activity of MDM2 and/or MDM4, or variants thereof, such as inflammatory or proliferative diseases or in the protection of cells.
  [FR] L'invention porte sur des composés 3-hétérocyclyl indolylés, capables d'inhiber l'interaction entre p53, ou des variantes de celui-ci, et MDM2 et/ou MDM4, ou des variantes de ceux-ci, respectivement, lesdits composés ayant la formule (I) dans laquelle R¹, R², R³, R⁴, R^A, Y et Y sont tels que définis dans la description. En raison de leur activité, les composés sont utiles dans le traitement de divers troubles et diverses maladies à médiation par l'activité de MDM2 et/ou MDM4, ou des variantes de ceux-ci, tels que des maladies inflammatoires ou prolifératives ou dans la protection de cellules.
• [EN] NAMPT MODULATORS<br/>[FR] MODULATEURS DE NAMPT
  申请人：CYTOKINETICS INC

  公开号：WO2021226276A2

  公开（公告）日：2021-11-11

  Provided are compounds of Formula (II): or a pharmaceutically acceptable salt thereof, wherein R1, n, and Y1 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (II), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (II), or a pharmaceutically acceptable salt thereof.
• Discovery and biological evaluation of adamantyl amide 11β-HSD1 inhibitors
  作者：Scott P. Webster、Peter Ward、Margaret Binnie、Eilidh Craigie、Kirsty M.M. McConnell、Karen Sooy、Andy Vinter、Jonathan R. Seckl、Brian R. Walker

  DOI：10.1016/j.bmcl.2007.02.057

  日期：2007.5

  A series of adamantyl amide 11 beta-HSD1 inhibitors has been discovered and chemically modified. Selected compounds are selective for 11 beta-HSD1 over 11 beta-HSD2 and possess excellent cellular potency in human and murine 11 beta-HSD1 assays. Good pharmacodynamic characteristics are observed in ex vivo assays. (c) 2007 Elsevier Ltd. All rights reserved.